Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HASPIN | Q8TF76 | 9/20 | 0.51 |
| ▸ | GSK3B | P49841 | 1/20 | 0.51 |
| ▸ | CLK1 | P49759 | 1/20 | 0.47 |
| ▸ | ERN1 | O75460 | 2/20 | 0.46 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.44 |
| ▸ | PLK1 | P53350 | 1/20 | 0.44 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.44 |
| ▸ | PLK2 | Q9NYY3 | 1/20 | 0.44 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.38 |
| ▸ | CDK9 | P50750 | 1/20 | 0.38 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.37 |
| ▸ | IMPDH2 | P12268 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12804385 | 0.80 | HASPIN (0.45) | HASPINGSK3BCLK1ERN1DAPK3 | |
| SCHEMBL6880218 | 0.80 | HASPIN (0.45) | HASPINGSK3BCLK1ERN1DAPK3 | |
| SCHEMBL6881715 | 0.80 | HASPIN (0.45) | HASPINGSK3BCLK1ERN1DAPK3 | |
| SCHEMBL27136433 | 0.80 | HASPIN (0.45) | HASPINGSK3BCLK1ERN1DAPK3 | |
| SCHEMBL17348530 | 0.78 | HASPIN (0.45) | HASPINGSK3BCLK1ERN1DAPK3 | |
| SCHEMBL25258523 | 0.78 | HASPIN (0.48) | HASPINGSK3BCLK1ERN1DAPK3 | |
| SCHEMBL1982292 | 0.78 | TSHR (0.60) | HASPINGSK3BCLK1ERN1DAPK3 | |
| SCHEMBL3589139 | 0.78 | HASPIN (0.54) | HASPINGSK3BCLK1ERN1DAPK3 | |
| SCHEMBL14423247 | 0.78 | HASPIN (0.54) | HASPINGSK3BCLK1ERN1DAPK3 | |
| SCHEMBL568019 | 0.78 | HASPIN (0.54) | HASPINGSK3BCLK1ERN1DAPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260062412-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING MYT1 INHIBITORY ACTIVITY | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2026-03-05 | — | — | US | disclosed |
| EP-4647424-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING MYT1 INHIBITORY ACTIVITY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-11-12 | — | — | EP | disclosed |
| WO-2024181437-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING MYT1 INHIBITORY ACTIVITY | 中外製薬株式会社 | 2024-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062412-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING MYT1 INHIBITORY ACTIVITY | MYT1, NTMT1, MYL6 | HASPIN 2567/4885GSK3B 1621/4885CLK1 1262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.